Anne-Marie Malfait

List of Publications by Year in Descending Order

72 papers	3,592 citations	34 h-index	59 g-index
85 ext. papers	4,187 ext. citations	5.2 avg, IF	5.68 L-index

#	Paper	IF	Citations
72	The Genesis of Pain in Osteoarthritis: Inflammation as a Mediator of Osteoarthritis Pain.. *Clinics in Geriatric Medicine*, **2022**, 38, 221-238	3.8	3
71	Pain in the Ehlers-Danlos syndromes: Mechanisms, models, and challenges. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2021**, 187, 429-445	3.1	2
70	Animal Models of Ehlers-Danlos Syndromes: Phenotype, Pathogenesis, and Translational Potential. *Frontiers in Genetics*, **2021**, 12, 726474	4.5	3
69	The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice. *Arthritis Research and Therapy*, **2021**, 23, 103	5.7	4
68	Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. *Rheumatic Disease Clinics of North America*, **2021**, 47, 165-180	2.4	5
67	Neuroimmune interactions and osteoarthritis pain: focus on macrophages. *Pain Reports*, **2021**, 6, e892	3.5	6
66	Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis. *Osteoarthritis and Cartilage*, **2020**, 28, 581-592	6.2	9
65	The innate immune response as a mediator of osteoarthritis pain. *Osteoarthritis and Cartilage*, **2020** , 28, 562-571	6.2	30
64	Pain-related behaviors and abnormal cutaneous innervation in a murine model of classical Ehlers-Danlos syndrome. *Pain*, **2020**, 161, 2274-2283	8	6
63	Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. *Pharmacology & Therapeutics*, **2020**, 211, 107553	13.9	13
62	Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. *Arthritis and Rheumatology*, **2019**, 71, 1276-1284	9.5	20
61	The nociceptive innervation of the normal and osteoarthritic mouse knee. *Osteoarthritis and Cartilage*, **2019**, 27, 1669-1679	6.2	21
60	An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. *Seminars in Immunopathology*, **2019**, 41, 583-594	12	19
59	Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. *Pain*, **2019**, 160, 2210-2220	8	41
58	The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 120, 130-134	2.2	7
57	Peripheral Mechanisms Contributing to Osteoarthritis Pain. *Current Rheumatology Reports*, **2018**, 20, 9	4.9	39
56	What is new in pain modification in osteoarthritis?. *Rheumatology*, **2018**, 57, iv99-iv107	3.9	37

55	Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. *Arthritis and Rheumatology*, **2018**, 70, 88-97	9.5	22
54	Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. *Journal of Orthopaedic Research*, **2018**, 36, 864-875	3.8	10
53	An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. *JCI Insight*, **2018**, 3,	9.9	50
52	Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?. *Current Opinion in Rheumatology*, **2017**, 29, 110-118	5.3	34
51	Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. *Arthritis and Rheumatology*, **2017**, 69, 1429-1439	9.5	31
50	Development of a Cartilage Shear-Damage Model to Investigate the Impact of Surface Injury on Chondrocytes and Extracellular Matrix Wear. *Cartilage*, **2017**, 8, 444-455	3	14
49	Spinal microglial activation in a murine surgical model of knee osteoarthritis. *Osteoarthritis and Cartilage*, **2017**, 25, 718-726	6.2	25
48	Osteoarthritis pain: What are we learning from animal models?. *Best Practice and Research in Clinical Rheumatology*, **2017**, 31, 676-687	5.3	22
47	Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 107, 85-87	2.2	22
46	Why we should study pain in animal models of rheumatic diseases. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 107, 37-39	2.2	2
45	Pain in rheumatic diseases. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 107, 1	2.2	
44	Osteoarthritis year in review 2015: biology. *Osteoarthritis and Cartilage*, **2016**, 24, 21-6	6.2	96
43	Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. *Osteoarthritis and Cartilage*, **2016**, 24, 299-306	6.2	49
42	Emerging Targets for the Management of Osteoarthritis Pain. *Current Osteoporosis Reports*, **2016**, 14, 260-268	5.4	38
41	The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. *Current Osteoporosis Reports*, **2015**, 13, 318-26	5.4	26
40	PCSK6-mediated corin activation is essential for normal blood pressure. *Nature Medicine*, **2015**, 21, 1048-53	30.5	83
39	Damage-associated molecular patterns generated in osteoarthritis directly excite murine nociceptive neurons through Toll-like receptor 4. *Arthritis and Rheumatology*, **2015**, 67, 2933-43	9.5	60
38	On the predictive utility of animal models of osteoarthritis. *Arthritis Research and Therapy*, **2015**, 17, 225	5.7	89

37	Osteoarthritis joint pain: the cytokine connection. *Cytokine*, **2014**, 70, 185-93	4	141
36	Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. *Current Rheumatology Reports*, **2013**, 15, 350	4.9	24
35	A commentary on modelling osteoarthritis pain in small animals. *Osteoarthritis and Cartilage*, **2013**, 21, 1316-26	6.2	96
34	Towards a mechanism-based approach to pain management in osteoarthritis. *Nature Reviews Rheumatology*, **2013**, 9, 654-64	8.1	182
33	Nanoparticles for improved local retention after intra-articular injection into the knee joint. *Pharmaceutical Research*, **2013**, 30, 257-68	4.5	56
32	Modelling pain in post-traumatic osteoarthritis of the knee. *Pain*, **2012**, 153, 257-258	8	2
31	CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 20602-7	11.5	167
30	A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. *Annals of the Rheumatic Diseases*, **2012**, 71, 1042-8	2.4	43
29	Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14. *Arthritis and Rheumatism*, **2012**, 64, 2268-77		65
28	Structure analysis reveals the flexibility of the ADAMTS-5 active site. *Protein Science*, **2011**, 20, 735-44	6.3	13
27	Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. *Archives of Biochemistry and Biophysics*, **2010**, 499, 32-9	4.1	33
26	ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. *Osteoarthritis and Cartilage*, **2010**, 18, 572-80	6.2	99
25	Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. *Journal of Biological Chemistry*, **2009**, 284, 24185-91	5.4	47
24	Intra-articular injection of tumor necrosis factor-alpha in the rat: an acute and reversible in vivo model of cartilage proteoglycan degradation. *Osteoarthritis and Cartilage*, **2009**, 17, 627-35	6.2	21
23	ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). *Arthritis and Rheumatism*, **2009**, 60, 2704-13		36
22	A review of the ADAMTS family, pharmaceutical targets of the future. *Current Pharmaceutical Design*, **2009**, 15, 2359-74	3.3	58
21	Proprotein convertase activation of aggrecanases in cartilage in situ. *Archives of Biochemistry and Biophysics*, **2008**, 478, 43-51	4.1	59
20	High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). *Journal of Biological Chemistry*, **2008**, 283, 1501-1507	5.4	59

19	Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. *Current Pharmaceutical Biotechnology*, **2008**, 9, 16-23	2.6	26
18	Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. *Arthritis and Rheumatism*, **2007**, 56, 575-85		316
17	A high performance liquid chromatography assay for monitoring proprotein convertase activity. *Journal of Chromatography A*, **2007**, 1148, 46-54	4.5	4
16	Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate. *Journal of Biological Chemistry*, **2007**, 282, 11101-9	5.4	39
15	Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3554-61	5.9	14
14	Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). *Biochemistry*, **2007**, 46, 6393-401	3.2	29
13	Identification of fibronectin neoepitopes present in human osteoarthritic cartilage. *Arthritis and Rheumatism*, **2006**, 54, 2912-22		42
12	ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. *Archives of Biochemistry and Biophysics*, **2005**, 444, 34-44	4.1	62
11	ADAMTS-4 and ADAMTS-5 **2005**, 299-322		2
10	Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. *Journal of Biological Chemistry*, **2004**, 279, 15434-40	5.4	88
9	Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. *Journal of Biological Chemistry*, **2004**, 279, 17554-61	5.4	98
8	Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. *Journal of Biological Chemistry*, **2002**, 277, 22201-8	5.4	230
7	Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. *Arthritis and Rheumatism*, **2001**, 44, 1215-24		44
6	The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. *Osteoarthritis and Cartilage*, **2001**, 9, 539-52	6.2	324
5	Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. *European Journal of Immunology*, **1999**, 29, 2205-12	6.1	80
4	Standardization of nutrient media for isolated human articular chondrocytes in gelified agarose suspension culture. *Osteoarthritis and Cartilage*, **1995**, 3, 249-59	6.2	21
3	Monoclonal Antibody Therapy in Rheumatoid Arthritis. *BioDrugs*, **1994**, 1, 148-156		1
2	T cell receptor V beta usage in rheumatoid nodules: marked oligoclonality among IL-2 expanded lymphocytes. *Clinical Immunology and Immunopathology*, **1993**, 68, 29-34		8

1 Size distribution of native aggrecan aggregates of human articular chondrocytes in agarose. *In Vitro Cellular and Developmental Biology - Animal*, **1993**, 29A, 356-8 2.6 4